Peptide & Experimental

Nicotine without smoke (pouches, patches, lozenges)

Nicotinic acetylcholine receptor agonist · nicotine pouches, pouches, nicotine replacement

In the laboratory, nicotine improves attention, reaction time and short-term memory – in a meta-analysis of 41 double-blind studies, in six of nine performance domains. The effect is real, small and lasts about an hour. The benefit of nicotine without smoke for quitting smoking is clearly established. Above the performance effect sits dependence, and there are no data on long-term use by non-smokers.

What nicotine without smoke is

This means nicotine taken in without combustion: via patches, chewing gum, lozenges or tobacco-free nicotine pouches placed between lip and gum. Patches, chewing gum and lozenges are approved as nicotine replacement for quitting smoking. In the biohacking scene, nicotine is also used as an aid for concentration and focus, including by people who have never smoked.

What is rated is the state of knowledge. Nicotine is well studied, both in performance research and as a replacement therapy. That is precisely why the result is robust: the performance effect is real, small and brief – and dependence is part of the finding.

How it works

Nicotine binds to nicotinic acetylcholine receptors in the brain. In the short term, this increases attention and reaction speed. Through the same receptors, nicotine activates the reward system, and this is the route by which dependence develops.

Effect and dependence therefore cannot be separated. The meta-analysis that demonstrates the performance effect draws exactly this conclusion: the cognitive advantage contributes to people starting to smoke and continuing.

What is well supported

A small, real performance effect. Across 41 double-blind, placebo-controlled laboratory studies, nicotine was better than placebo in six of nine performance domains, with effect sizes of 0.16 to 0.44. The participants were healthy adult non-smokers and smokers with no withdrawal or at most two hours of withdrawal – so the advantage is not merely relief of withdrawal symptoms.
Benefit for quitting smoking. Nicotine replacement increases the chance of quitting smoking for good by 50 to 60 percent. This rests on 133 randomized trials with 64,640 participants; the Cochrane authors rate the evidence as high quality. This is the use with a clear benefit.
Fewer harmful substances than smoking. Without combustion, tar and carbon monoxide are eliminated, and with them the main part of the harm from smoking.
A broad base of safety data. Side effects of nicotine replacement are known from more than a hundred randomized trials. Well studied does not mean harmless here.

What the studies show

Performance: six of nine domains, small effects

Heishman 2010 (Psychopharmacology) analyzed 41 double-blind, placebo-controlled laboratory studies from the years 1994 to 2008. For nine performance domains, the data were sufficient for a meta-analysis. Nicotine was significantly better than placebo for fine motor skills, the accuracy and reaction time of alerting attention, the reaction time of orienting attention, the accuracy of short-term episodic memory and the reaction time of working memory. The effect sizes ranged from 0.16 to 0.44. The authors consider the effects to be a genuine performance enhancement and, in the same sentence, name their significance for the initiation and maintenance of tobacco dependence.

Quitting smoking: 133 studies, a clear result

Hartmann-Boyce 2018 (Cochrane) pooled 133 randomized trials with 64,640 participants that compared nicotine replacement with placebo or with no replacement, with follow-up of at least six months. The risk ratio for quitting smoking for good was 1.55 (95 percent confidence interval 1.49 to 1.61). For chewing gum it was 1.49, for patches 1.64, for tablets and lozenges 1.52. The authors consider it very unlikely that further research will change this result.

Nicotine pouches: high doses, rapid uptake

Mallock-Ohnesorg 2024 (Frontiers in Pharmacology) had 15 regular smokers use pouches with 6, 20 and 30 milligrams of nicotine for 20 minutes in a crossover design, compared with nicotine-free pouches and cigarettes. The 30-milligram pouch led to a higher nicotine level than the cigarette: peak value 29.4 versus 15.2 nanograms per milliliter, area under the curve 45.7 versus 22.1. Pulse rose by about 27, 12 and 25 beats per minute with the cigarette, the 20-milligram pouch and the 30-milligram pouch, and measures of vascular stiffness were elevated. The craving for a cigarette fell with all products, including the nicotine-free pouch. The authors consider an upper limit on nicotine content to be warranted.

Where the data stop

Long-term use by non-smokers. There are no data on regular nicotine as a focus aid, neither on benefit nor on harm. The performance studies measure acute effects in the laboratory.
Benefit in everyday life. The effect sizes of 0.16 to 0.44 come from laboratory tests and apply for about an hour. Whether this translates into a noticeable advantage at work or in learning has not been studied.
Performance without dependence. The same paper that demonstrates the effect describes it as part of what maintains dependence. A dose that delivers the advantage without causing dependence has not been shown.
Adolescents. Starting via nicotine pouches is a separate problem among adolescents. The 2025 Drug Affinity Study (Drogenaffinitätsstudie) records it separately.

Status, approval and legal

Nicotine replacement products such as patches, chewing gum and lozenges are approved. Their intended purpose is quitting smoking.

Tobacco-free nicotine pouches may not be marketed as food in Germany. Anyone who advertises or sells them in this country is operating outside the approved framework.

Safety

The central risk is dependence. Through it, smoking has become the largest preventable cause of death. A non-smoker who uses nicotine for concentration accepts this risk for a small, brief effect.

With nicotine replacement, the side effects depend on the form of administration: skin irritation with patches, irritation in the mouth with chewing gum and lozenges. Chest pain or palpitations occurred more often in the Cochrane review than in the control group (odds ratio 1.88; 1.37 to 2.57), but were rare in both groups. Serious side effects were extremely rare.

With nicotine pouches, the measured doses of individual products are high. A 30-milligram pouch delivered more nicotine than a cigarette, raised the pulse markedly and had the strongest side effects overall. This text is information and does not replace medical advice.

BK-Score Well studied – effect not confirmed

Human evidence		8
Mechanism		9
Safety data		8
Hype gap		7
Track record of use		8

The acute effect is well supported and small: a meta-analysis of 41 double-blind studies (Heishman, Psychopharmacology 2010) found an advantage in six of nine performance domains, including fine motor skills, attention, reaction time and short-term memory, effect sizes 0.16 to 0.44 – in the laboratory, for about an hour. This very paper names dependence as an associated finding. The safety data are good: nicotine replacement has been tested in more than a hundred randomized trials (Cochrane 2018). That means well studied, not harmless. The direction remains negative because above the small, brief effect sits dependence – and this dependence is the reason why smoking is the largest preventable cause of death. There are no data on long-term use by non-smokers. For quitting smoking, by contrast, nicotine replacement is proven effective (Cochrane 2018) – that is the one use with a clear benefit. Tobacco-free nicotine pouches may not be marketed in Germany.

The score rates the state of knowledge, not the substance. “Safety data 9” means well studied – not harmless. “Track record of use 9” means used long and widely – that is not proof of efficacy.
Subjective assessment by Biohacking Kompakt based on published scoring rules – not a scientific rating and not a medical recommendation. Rules and all ratings (German)

Frequently asked questions about nicotine without smoke (pouches, patches, lozenges)

Does nicotine really improve concentration?

In the laboratory, yes, to a small extent. A meta-analysis of 41 double-blind, placebo-controlled studies found an advantage in six of nine performance domains, including fine motor skills, attention, reaction time and short-term memory. The effect sizes ranged from 0.16 to 0.44, and the effect lasts about an hour. There are no data from everyday life or on long-term use.

Is nicotine without smoke harmless?

No. Without combustion, tar and carbon monoxide are eliminated, and with them the main part of the harm from smoking. Nicotine itself, however, causes dependence, and it is precisely this dependence that keeps people smoking. There are no data on long-term use by non-smokers, neither on benefit nor on harm.

Does nicotine replacement help with quitting smoking?

Yes, that is well supported. A Cochrane review with 133 studies and 64,640 participants found a risk ratio of 1.55 for quitting smoking for good for all forms of nicotine replacement combined. The success rate thus rises by 50 to 60 percent, regardless of how much additional support there was.

Are nicotine pouches allowed in Germany?

No. Tobacco-free nicotine pouches may not be marketed in Germany. Nicotine replacement products such as patches, chewing gum and lozenges intended for quitting smoking, by contrast, are approved.

How much nicotine is in a nicotine pouch?

That varies widely. In a study with 15 smokers, a pouch with 30 milligrams of nicotine delivered a higher peak blood level than a cigarette, 29.4 versus 15.2 nanograms per milliliter. Pulse rose by about 25 beats per minute, and all pouches irritated the oral mucosa.

Same sectionEloralintide
Same sectionKetamine and esketamine (Spravato)
Same sectionArgireline (acetyl hexapeptide-8)
Same sectionZopiclone
Same sectionSalbutamol
Same sectionNoopept

Sources

Open in the database – with search, filters and comparison (German app)

Information only, not medical advice and not a usage or dosage recommendation. Prescription-only and unapproved substances belong in the hands of a physician. Last updated: 2026-10-05.